title: A perpetual source of DNA or something really different: ethical issues in the creation of cell lines for African genomics research.
abstract: BACKGROUND
  The rise of genomic studies in Africa - not least due to projects funded under H3Africa - is associated with the development of a small number of biorepositories across Africa. For the ultimate success of these biorepositories, the creation of cell lines including those from selected H3Africa samples would be beneficial. In this paper, we map ethical challenges in the creation of cell lines.
  
  
  CONCLUSIONS
  The first challenge we identified relates to the moral status of cells living in culture. There is no doubt that cells in culture are alive, and the question is how this characteristic is relevant to ethical decision-making. The second challenge relates to the fact that cells in culture are a source of cell products and mitochondrial DNA. In combination with other technologies, cells in culture could also be used to grow human tissue. Whilst on the one hand, this feature increases the potential utility of the sample and promotes science, on the other it also enables further scientific work that may not have been specifically consented to or approved. The third challenge relates to ownership over samples, particularly in cases where cell lines are created by a biobank, and in a different country than where samples were collected. Relevant questions here concern the export of samples, approval of secondary use and the acceptability of commercialisation. A fourth challenge relates to perceptions of blood and bodily integrity, which may be particularly relevant for African research participants from certain cultures or backgrounds. Finally, we discuss challenges around informed consent and ethical review.
  
  
  CONCLUSIONS
  In this paper, we sought to map the myriad of ethical challenges that need to be considered prior to making cell line creation a reality in the H3Africa project. Considering the relative novelty of this practice in Africa, such challenges will need to be considered, discussed and potentially be resolved before cell line creation in Africa becomes financially feasible and sustainable. We suggest that discussions need to be undertaken between stakeholders internationally, considering the international character of the H3Africa project. We also map out avenues for empirical research.
authors.affiliation: Department of Medicine, University of Cape Town, Office J52-16, UCT Centre for Clinical Research, Old Main Building, Groote Schuur Hospital, Observatory, 7925 Cape Town, South Africa. Jantina.devries@uct.ac.za.
authors.forename: Jantina
authors.initials: J
authors.lastname: de Vries
authors.forename: Akin
authors.initials: A
authors.lastname: Abayomi
authors.forename: James
authors.initials: J
authors.lastname: Brandful
authors.forename: Katherine
authors.initials: K
authors.lastname: Littler
authors.forename: Ebony
authors.initials: E
authors.lastname: Madden
authors.forename: Patricia
authors.initials: P
authors.lastname: Marshall
authors.forename: Odile
authors.initials: O
authors.lastname: Ouwe Missi Oukem-Boyer
authors.forename: Janet
authors.initials: J
authors.lastname: Seeley
mesh_terms: D000349:Africa; D026688:Bioethical Issues; D018070:Biological Specimen Banks / Q000941:ethics*; D044383:Black People / Q000235:genetics*; D002460:Cell Line; D003469:Culture; D004247:DNA; D026724:Ethical Review; D036281:Genetic Research / Q000941:ethics*; D023281:Genomics / Q000941:ethics*; D006801:Humans; D007258:Informed Consent; D010067:Ownership
chemical_list: D004247:DNA
references.citation: Nature. 2007 Jul 19;448(7151):313-7
references.pmid: 17554338
references.citation: J Med Ethics. 2009 Feb;35(2):125-9
references.pmid: 19181887
references.citation: Nature. 2010 Oct 28;467(7319):1061-73
references.pmid: 20981092
references.citation: Trans R Soc Trop Med Hyg. 2013 Apr;107(4):261-5
references.pmid: 23426114
references.citation: Hastings Cent Rep. 1998 Sep-Oct;28(5):30-9
references.pmid: 11656768
references.citation: J Empir Res Hum Res Ethics. 2013 Oct;8(4):1-18
references.pmid: 24169417
references.citation: J Blood Med. 2012;3:87-96
references.pmid: 22977316
references.citation: N Engl J Med. 2010 Jul 15;363(3):204-7
references.pmid: 20538622
references.citation: J Med Ethics. 2012 Aug;38(8):474-8
references.pmid: 22493187
references.citation: BMC Med Ethics. 2012 Jul 02;13:15
references.pmid: 22747883
references.citation: Dev World Bioeth. 2011 Dec;11(3):120-7
references.pmid: 21781234
references.citation: Science. 2007 Dec 21;318(5858):1917-20
references.pmid: 18029452
references.citation: PLoS Med. 2008 Sep 16;5(9):e192
references.pmid: 18798689
references.citation: Bioessays. 2013 Feb;35(2):131-40
references.pmid: 23281054
references.citation: Soc Sci Med. 2004 Dec;59(12):2547-59
references.pmid: 15474208
references.citation: BMC Med Ethics. 2014 May 13;15:38
references.pmid: 24885380
references.citation: Science. 1999 Nov 19;286(5444):1475
references.pmid: 10610545
references.citation: BMC Med Ethics. 2013 Sep 11;14:35
references.pmid: 24025667
references.citation: Nature. 2007 Oct 18;449(7164):851-61
references.pmid: 17943122
references.citation: Dev World Bioeth. 2009 Dec;9(3):138-48
references.pmid: 18452553
references.citation: Am J Public Health. 2006 Nov;96(11):1989-95
references.pmid: 17018820
references.citation: Natl Cathol Bioeth Q. 2002 Autumn;2(3):381-9
references.pmid: 12854595
references.citation: Soc Sci Med. 2012 Oct;75(8):1400-7
references.pmid: 22749442
references.citation: N Engl J Med. 2002 Jun 20;346(25):2002-5
references.pmid: 12075064
references.citation: Hum Mol Genet. 2013 Oct 15;22(R1):R22-6
references.pmid: 23922233